Update on the metabolic syndrome: Hypertension

Current Hypertension Reports

Volumn 11, Issue 2, 2009, Pages 150-155

  Reynolds, Kristi ^a   Wildman, Rachel P ^a  

^a Kaiser Permanente Southern California   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; CHLORTALIDONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; INDAPAMIDE; LISINOPRIL; PERINDOPRIL; PLACEBO; RAMIPRIL; THIAZIDE DIURETIC AGENT; ZOFENOPRIL;

ANTIHYPERTENSIVE THERAPY; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; DIABETES MELLITUS; DISEASE COURSE; DRUG MECHANISM; GLUCOSE INTOLERANCE; HIGH RISK PATIENT; HUMAN; HYPERTENSION; LIFESTYLE MODIFICATION; METABOLIC SYNDROME X; MORTALITY; PRACTICE GUIDELINE; PREVALENCE; REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS;

ANTIHYPERTENSIVE AGENTS; CARDIOVASCULAR DISEASES; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; HYPERTENSION; INSULIN RESISTANCE; LIFE STYLE; MALE; METABOLIC SYNDROME X; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RISK FACTORS;

EID: 62549122501     PISSN: 15226417     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11906-009-0026-5     Document Type: Review

References (49)

1. International Diabetes Federation: The IDF consensus worldwide definition of the metabolic syndrome. Available at http://www.idf.org/ webdata/docs/MetS_def_update2006.pdf. Accessed October 2008.
2. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III): Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002, 106:3143-3421.
3. Alberti KG, Zimmet PZ: Definition, diagnosis and classification of diabetes mellitus and its complications. Part 1: Diagnosis and classification of diabetes mellitus provisional report of a WHO consultation. Diabet Med 1998, 15:539-553.
4. Einhorn D, Reaven GM, Cobin RH, et al.: American College of Endocrinology position statement on the insulin resistance syndrome. Endocr Pract 2003, 9:237-252.
5. Grundy SM, Cleeman JI, Daniels SR, et al.: Diagnosis and management of the metabolic syndrome: An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement. Circulation 2005, 112:2735-2752.
6. Ford ES, Giles WH, Mokdad AH: Increasing prevalence of the metabolic syndrome among US adults. Diabetes Care 2004, 27:2444-2449.
7. Fields LE, Burt VL, Cutler JA, et al.: The burden of adult hypertension in the United States 1999 to 2000: A rising tide. Hypertension 2004, 44:398-404.
8. Vasan RS, Beiser A, Seshadri S, et al.: Residual lifetime risk for developing hypertension in middle-aged women and men: The Framingham Heart Study. JAMA 2002, 287:1003-1010.
9. McNeill AM, Rosamond WD, Girman CJ, et al.: The metabolic syndrome and 11-year risk of incident cardiovascular disease in the atherosclerosis risk in communities study. Diabetes Care 2005, 28:385-390.
10. Vaidya D, Szklo M, Liu K, et al.: Defining the metabolic syndrome construct: Multi-Ethnic Study of Atherosclerosis (MESA) cross-sectional analysis. Diabetes Care 2007, 30:2086-2090.
11. Rutter MK, Meigs JB, Sullivan LM, et al.: Insulin resistance, the metabolic syndrome, and incident cardiovascular events in the Framingham Offspring Study. Diabetes 2005, 54:3252-3257.
12. Leoncini G, Ratto E, Viazzi F, et al.: Metabolic syndrome is associated with early signs of organ damage in nondiabetic, hypertensive patients. J Intern Med 2005, 257:454-460.
13. Pannier B, Thomas S, Bean K, et al.: The metabolic syndrome: similar deleterious impact on all-cause mortality in hypertensive and normotensive subjects. J Hypertens 2008, 26:1223-1228.
14. Schillaci G, Pirro M, Vaudo G, et al.: Prognostic value of the metabolic syndrome in essential hypertension. J Am Coll Cardiol 2004, 43:1817-1822.
15. Vlek AL, van der Graaf Y, Spiering W, et al.: SMART study group: Effect of metabolic syndrome or type II diabetes mellitus on the occurrence of recurrent vascular events in hypertensive patients. J Hum Hypertens 2008, 22:358-365.
16. Ford ES: Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: A summary of the evidence. Diabetes Care 2005, 28:1769-1778.
17. Galassi A, Reynolds K, He J: Metabolic syndrome and risk of cardiovascular disease: A meta-analysis. Am J Med 2006, 119:812-819.
18. Ho JS, Cannaday JJ, Barlow CE, et al.: Relation of the number of metabolic syndrome risk factors with all-cause and cardiovascular mortality. Am J Cardiol 2008, 102:689-692.
19. Hsu PF, Chuang SY, Cheng HM, et al.: Clinical significance of the metabolic syndrome in the absence of established hypertension and diabetes: A community-based study. Diabetes Res Clin Pract 2008, 79:461-467.
20. Mozaffarian D, Kamineni A, Prineas RJ, Siscovick DS: Metabolic syndrome and mortality in older adults: The Cardiovascular Health Study. Arch Intern Med 2008, 168:969-978.
21. Mancia G, Bombelli M, Corrao G, et al.: Metabolic syndrome in the Pressioni Arteriose Monitorate E Loro Associazioni (PAMELA) study: Daily life blood pressure, cardiac damage, and prognosis. Hypertension 2007, 49:40-47.
22. Hong Y, Jin X, Mo J, et al.: Metabolic syndrome, its preeminent clusters, incident coronary heart disease and all-cause mortality-results of prospective analysis for the Atherosclerosis Risk in Communities study. J Intern Med 2007, 262:113-122.
23. Chobanian AV, Bakris GL, Black HR, et al.: The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 report. JAMA 2003, 289:2560-2572.
24. Appel LJ, Moore TJ, Obarzanek E, et al.: A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 1997, 336:1117-1124.
25. Azadbakht L, Mirmiran P, Esmaillzadeh A, et al.: Beneficial effects of a Dietary Approaches to Stop Hypertension eating plan on features of the metabolic syndrome. Diabetes Care 2005, 28:2823-2831.
26. Lien LF, Brown AJ, Ard JD, et al.: Effects of PREMIER lifestyle modifications on participants with and without the metabolic syndrome. Hypertension 2007, 50:609-616.
27. Whelton SP, Chin A, Xin X, He J: Effect of aerobic exercise on blood pressure: A meta-analysis of randomized, controlled trials. Ann Intern Med 2002, 136:493-503.
28. Pescatello LS, Blanchard BE, Van Heest JL, et al.: The metabolic syndrome and the immediate antihypertensive effects of aerobic exercise: a randomized control design. BMC Cardiovasc Disord 2008, 8:12.
29. Mourad JJ, Lameira D, Guillausseau PJ: Blood pressure normalization by fixed perindopril/indapamide combination in hypertensive patients with or without associate metabolic syndrome: Results of the OPTIMAX 2 study. Vasc Health Risk Manag 2008, 4:443-451.
30. Malacco E, Omboni S: Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndrome. Adv Ther 2007, 24:1006-1015.
31. Rossi R, Nuzzo A, Origliani G, Modena MG: Metabolic syndrome affects cardiovascular risk profile and response to treatment in hypertensive postmenopausal women. Hypertension 2008, 52:865-872.
32. Redon J, Cifkova R: The metabolic Dyndrome in hypertension: diagnostic and therapeutic implications. Curr Hypertens Rep 2007, 9:305-313.
33. Gress TW, Nieto FJ, Shahar E, et al.: Hypertension and antihypertensive therapy as risk factors for type 2 diabetes mellitus. Atherosclerosis Risk in Communities Study. N Engl J Med 2000, 342:905-912.
34. Hansson L, Lindholm LH, Niskanen L, et al.: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999, 353:611-616.
35. Yusuf S, Gerstein H, Hoogwerf B, et al.: Ramipril and the development of diabetes. JAMA 2001, 286:1882-1885.
36. Messerli FH, Grossman E, Leonetti G: Antihypertensive therapy and new onset diabetes. J Hypertens 2004, 22:1845-1847.
37. Mancia G, Grassi G, Zanchetti A. New-onset diabetes and antihypertensive drugs. J Hypertens 2006, 24:3-10.
38. Opie LH, Schall R: Old antihypertensives and new diabetes. J Hypertens 2004, 22:1453-1458.
39. Mason JM, Dickinson HO, Nicolson DJ, et al.: The diabetogenic potential of thiazide-type diuretic and beta-blocker combinations in patients with hypertension. J Hypertens 2005, 23:1777-1781.
40. Kostis JB, Wilson AC, Freudenberger RS, et al.: Long-term effect of diuretic-based therapy on fatal outcomes in subjects with isolated systolic hypertension with and without diabetes. Am J Cardiol 2005, 95:29-35.
41. Barzilay JI, Davis BR, Cutler JA, et al.: Fasting glucose levels and incident diabetes mellitus in older nondiabetic adults randomized to receive 3 different classes of antihypertensive treatment: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2006, 166:2191-2201.
42. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. UK Prospective Diabetes Study Group. BMJ 1998, 317:713-720.
43. Turnbull F, Neal B, Algert C, et al.: Effects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: Results of prospectively designed overviews of randomized trials. Arch Intern Med 2005, 165:1410-1419.
44. Black HR, Davis B, Barzilay J, et al.: Metabolic and clinical outcomes in nondiabetic individuals with the metabolic syndrome assigned to chlorthalidone, amlodipine, or lisinopril as initial treatment for hypertension: A report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Diabetes Care 2008, 31:353-360.
45. Wright JT Jr, Harris-Haywood S, Pressel S, et al.: Clinical outcomes by race in hypertensive patients with and without the metabolic syndrome: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med 2008, 168:207-217.
46. Hilgers KF, Mann JF: The choice of antihypertensive therapy in patients with the metabolic syndrome - time to change recommendations? Nephrol Dial Transplant 2008, 23:3389-3391.
47. Kahn R: MetaboIic syndrome: is it a syndrome? Does it matter? Circulation 2007, 115:1806-1810.
48. Kahn R, Buse J, FeTrannini E, Stern M: The metabolic syndrome: time for a critical appraisal: Joint statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2005, 28:2289-2304.
49. Greenland P: Critical questions about the metabolic syndrome. Circulation 2005, 112:3675-3676.